Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
Kazuyuki Numakura(Akita University), Tomonori Habuchi(Akita University), Shingo Hatakeyama(Hirosaki University), Akihiro Ito(Tohoku University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Sei Naito(Yamagata University), Norihiko Tsuchiya(Yamagata University), Renpei Kato(Iwate Medical University), Wataru Obara(Iwate Medical University), Takahiro Kojima(Aichi Cancer Center), Yumin Muto(Akita University), Hiroyuki Nishiyama(University of Tsukuba), Chikara Οhyama(Hirosaki University), Yoichi Arai(Japan Atomic Energy Agency), Yoshihide Kawasaki(Tohoku University), Shuya Kandori(University of Tsukuba), Yoshiyuki Kojima(Fukushima Medical University), Tomoyuki Koguchi(Fukushima Medical University)
Cited by 22
Related Papers
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603